VIAN Therapeutics is a technology company.
VIAN Therapeutics has raised $1.3M across 2 funding rounds.
VIAN Therapeutics has raised $1.3M in total across 2 funding rounds.
VIAN Therapeutics has raised $1.3M in total across 2 funding rounds.
VIAN Therapeutics's investors include Babel Ventures, ExSight Capital Management, Mayfield, Social Starts, SOSV.
ViAn Therapeutics is a clinical-stage pharmaceutical company developing non-invasive, topical eye drop treatments for retinal blinding diseases like diabetic retinopathy and age-related macular degeneration (AMD).[1][3][5] Its lead product, VIAN-c4551 (or c4551), is a highly potent, cyclic anti-angiogenic peptide that inhibits vascular permeability and angiogenesis in the retina, offering a convenient alternative to invasive intravitreal injections.[1][2][3][4][5] Founded in 2023 and based in San Francisco (with early ties to Berkeley), the company targets the $12B anti-VEGF ophthalmology market, where up to 50% of patients do not respond to current standards, by addressing unmet needs in mild-to-moderate cases through daily at-home drops with exceptional ocular penetration.[1][3][4] Backed by $275K in seed funding from accelerators like SOSV and IndieBio, ViAn serves ophthalmologists and patients seeking safer, easier therapies, showing early momentum with pre-IND studies in rabbits and a patented peptide naturally found in the body.[3][4]
ViAn Therapeutics emerged from three decades of pioneering angiogenesis research at the National University of Mexico, where founder and CEO Juan Pablo Robles Alvarez, M.Sc., Ph.D., discovered the key anti-angiogenic peptide after a decade of focused work in oncology and ophthalmology.[2][3][5] A scientist-entrepreneur from Queretaro, Mexico, Robles honed his vision through programs like UCSF Global Entrepreneurship, Nucleate, and IndieBio, translating lab insights into a virtual pharma startup launched in 2023.[2][5] Pivotal early traction came via IndieBio and SOSV investments, enabling proof-of-concept for the peptide's topical efficacy, with advisor Napoleone Ferrara, MD—discoverer of VEGF and a giant in the field—providing strategic guidance to bridge academic breakthroughs to market-disrupting therapies.[3][4][5]
ViAn rides the wave of next-generation ophthalmology, targeting the exploding demand for non-invasive retinal therapies amid aging populations and rising diabetes rates driving AMD and retinopathy prevalence.[1][3][4] Timing is ideal as blockbuster anti-VEGF patents expire, spurring pharma to innovate beyond injections—ViAn's peptide disrupts this $12B+ market by unlocking early-stage treatment for 50% of non-responders, expanding access via at-home drops.[3][4] Favorable forces include advances in peptide stability for ocular delivery and accelerator ecosystems like IndieBio accelerating biotech from bench to clinic; ViAn influences the landscape by validating "beyond VEGF" multi-target approaches, potentially inspiring oral/topical shifts in oncology and other angiogenesis-driven diseases.[2][4][5]
ViAn is poised for Seed VC expansion and IND filing, leveraging rabbit safety data into human trials to prove eye drop superiority, with milestones like partnerships or Series A by 2026 amid patent expirations creating tailwinds.[1][3][4] Trends like peptide therapeutics, AI-accelerated drug design, and telemedicine ophthalmology will amplify its trajectory, evolving ViAn from virtual startup to category leader in convenient retinal care. As Robles' discovery redefines vision protection, ViAn exemplifies how academic ingenuity, fueled by top accelerators, challenges invasive norms—unlocking broader access just as demographics demand it.[5]
VIAN Therapeutics has raised $1.3M across 2 funding rounds. Most recently, it raised $1.0M Seed in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $1.0M Seed | Babel Ventures, ExSight Capital Management, Mayfield, Social Starts, SOSV | |
| Jun 1, 2023 | $280K Seed | Babel Ventures, ExSight Capital Management, Mayfield, Social Starts, SOSV |